17,261 trials
Peripheral T-cell Lymphoma
Primary: Percentage of Participants With a Complete Response According to the International Workshop Response Criteria (IWC) for Non-Hodgkin's Lymphomas (NHL) Assessed by an…
Reflux
Primary: Reflux Episodes 0 to 3 Hours Post Meal — 15.1; 12.5; 11.0; 12.7 Episodes
B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Primary: Number of Participants With Best Disease Response as Determined by the Independent Response Review Panel (IRRP) — 37; 5; 32; 24 participants
Squamous Cell Carcinoma of the Head and Neck
Primary: Best Overall Response (BOR) According to Modified World Health Organization (WHO) Criteria — 36.4 percentage of participants
Parkinson Disease
Primary: Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 24 Assessed Off Medication. — -3.57; 1.85 Scores on a scale…
HTLV-I Infection · T Cell Leukemia
Primary: Duration of Response — 114 Weeks
Prostate Cancer
Primary: Change in Serum Prostate Specific Antigen (PSA) of Prostate Cancer — 0.86 ng/mL — p==0.027
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Progression-free Survival (PFS) Rate at 12 Months — 79 percentage of participants
Cancer of the Esophagus
Primary: Panitumumab Maximum Tolerated Dose in Milligrams (mg) — 3.6 mg
Leukemia · Lymphoma
Primary: Number of Participants With Absolute Neutrophil Count Engraftment — 21 participant
Rheumatoid Arthritis
Primary: Number of Participants Meeting the American College of Rheumatology 20 (ACR 20) Response at Week 16 — 13; 21; 17; 19 Participants — p=0.010
H1N1 Influenza Virus
Primary: Percentage of Participants With Serious Adverse Events (SAEs) Attributed To Vaccination — 1; 0; 3; 0 percentage of participants
Cystinuria · Nephrolithiasis, Calcium Oxalate
Primary: 24 Hour Urine Supersaturation of Calcium Oxalate (CaOx) — 1.83; 1.83; 1.87; 1.78 KJoules/mol — p=0.32
Heart Failure, Diastolic
Primary: Diastolic Circumferential Strain Rate During Isovolumic Relaxation — 0.61; 0.37; 0.34 1/sec
End Stage Renal Failure on Dialysis
Primary: Primary Endpoint Will be the Number of Tea Tree Oil Patients That Did Not Have a Catheter-related Infection Within 6 Months After Entry Into the Trial. — 0 participants